HC Wainwright Comments on Alumis’ Q1 Earnings (NASDAQ:ALMS)

Alumis Inc. (NASDAQ:ALMS) – Equities researchers at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of Alumis in a research note issued to investors on Monday, March 30th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.70) for the quarter, up from their prior estimate of ($0.71). HC Wainwright currently has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis’ Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.82) EPS and FY2026 earnings at ($2.89) EPS.

ALMS has been the subject of several other research reports. Citigroup reissued an “outperform” rating on shares of Alumis in a research note on Tuesday, January 6th. Leerink Partners raised their price target on shares of Alumis from $20.00 to $32.00 and gave the company an “outperform” rating in a research note on Tuesday, January 6th. Stifel Nicolaus began coverage on shares of Alumis in a report on Wednesday, February 25th. They set a “buy” rating and a $44.00 price target on the stock. Wall Street Zen upgraded shares of Alumis from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Finally, Morgan Stanley increased their price objective on shares of Alumis from $33.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, March 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Alumis currently has a consensus rating of “Moderate Buy” and an average price target of $38.60.

Alumis Stock Up 9.0%

NASDAQ:ALMS opened at $22.03 on Wednesday. The stock’s 50-day simple moving average is $26.42 and its 200 day simple moving average is $14.79. The firm has a market capitalization of $2.80 billion, a PE ratio of -7.20 and a beta of -2.15. Alumis has a twelve month low of $2.76 and a twelve month high of $30.60.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). Alumis had a negative return on equity of 116.97% and a negative net margin of 1,011.75%.The business had revenue of $1.93 million for the quarter, compared to analyst estimates of $2.75 million.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ALMS. Samsara Biocapital LLC boosted its position in Alumis by 19.9% during the 4th quarter. Samsara Biocapital LLC now owns 5,756,984 shares of the company’s stock worth $56,188,000 after buying an additional 955,614 shares during the period. Vanguard Group Inc. increased its position in Alumis by 18.4% in the 3rd quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company’s stock valued at $16,078,000 after acquiring an additional 625,404 shares during the period. Cormorant Asset Management LP increased its position in Alumis by 69.3% in the 4th quarter. Cormorant Asset Management LP now owns 3,635,596 shares of the company’s stock valued at $35,483,000 after acquiring an additional 1,488,200 shares during the period. Trium Capital LLP raised its stake in shares of Alumis by 17.9% during the third quarter. Trium Capital LLP now owns 3,122,111 shares of the company’s stock valued at $12,457,000 after acquiring an additional 474,072 shares during the last quarter. Finally, MPM Bioimpact LLC bought a new position in shares of Alumis during the fourth quarter valued at $23,443,000.

Insider Transactions at Alumis

In other news, Director Srinivas Akkaraju bought 588,235 shares of the company’s stock in a transaction on Friday, January 9th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $9,999,995.00. Following the completion of the transaction, the director owned 1,853,488 shares of the company’s stock, valued at $31,509,296. This trade represents a 46.49% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Foresite Capital Management Vi purchased 411,764 shares of the business’s stock in a transaction dated Thursday, January 8th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $6,999,988.00. Following the completion of the purchase, the insider directly owned 5,702,536 shares of the company’s stock, valued at approximately $96,943,112. This represents a 7.78% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 1,823,527 shares of company stock worth $30,999,959 in the last 90 days. 40.70% of the stock is currently owned by company insiders.

Alumis News Roundup

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Oppenheimer raised its price target sharply to $55 and kept an “outperform” rating, signaling substantial upside vs. the current share level and supporting buying interest. Article Title
• Positive Sentiment: Chardan Capital reaffirmed its “buy” rating with a $38 price target, reiterating institutional conviction and adding support for bullish flows. Article Title
• Positive Sentiment: Morgan Stanley (via a TipRanks summary) maintained a Buy rating and $38 target, citing strong Phase‑3 data for Envu and an attractive risk/reward ahead of a planned 2026 FDA submission — a clinical/data catalyst that underpins upside expectations. Article Title
• Neutral Sentiment: HC Wainwright issued FY2027 EPS estimates of ($3.37) and kept a “Buy” rating with a $25 target — the EPS forecast is materially less negative than the consensus (-$8.51), which could be read as relatively constructive, but the figure is still negative and reflects ongoing cash burn/near‑term losses.
• Negative Sentiment: HC Wainwright cut its prior price target from $40 to $25 while retaining a buy rating, a mixed signal that reduces some upside expectations and may have pressured shorter‑term sentiment. Article Title
• Negative Sentiment: On 3/30 ALMS fell roughly 11% amid profit‑taking after a ~239% yearly gain; technical selling and traders locking gains were cited as drivers of the pullback. That short‑term volatility can amplify moves when headlines on ratings/targets hit the tape. Why Is Alumis Stock Falling Monday?

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.